Anti-CD20 Monoclonal Antibodies Market, By Product Type (First Generation Anti-CD20 Monoclonal Antibodies, Second Generation Anti-CD20 Monoclonal Antibodies and Third Generation Anti-CD20 Monoclonal Antibodies), By End-User (Hospitals, Clinics, Academic & Research Institutions and Contract Research Organization (CRO’s)), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2034

Anti-CD20 Monoclonal Antibodies Market was valued at US$ 9.0 billion in 2024 and is projected to grow at a CAGR of 9.0% to reach US$ 19.8 billion by 2034.

Anti-CD20 are generally used in the treatment of B-cell malignancies which works by targeting expressed CD20 marker on mature B cells and malignant B cells. This cascade of series work by complementing with marker to deliver immunological attack from complement and FcR-expressing innate effectors (macrophages). This result in producing transmembrane signals by CD20 on engagement with anti-CD20 monoclonal antibodies, this favorable mechanism is utilized in malignant disease and autoimmune disorder treatment.  Potential benefits from anti-CD20 monoclonal antibodies laid emphasis on developing next-generation anti-CD20 monoclonal antibodies and are currently in clinical trials.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Anti-CD20 dual nature

Anti-CD20 monoclonal antibodies are used for the treatment of B-cell malignancies due to its advantage as they enhance killing activities and improves CD-20 levels on cell surface to increase the activity of lymphoma therapy which further boost the market.

Increasing prevalence of cancer patients

The increase in mortality and morbidity rates among patients is one of the driver of this market. For instance, according to the WHO, there are approximately 14 million cancer cases every year and the rates are constantly increasing. Almost 1.9 million new cancer cases are expected to be diagnosed in 2021.

However, technical and clinical-related challenges might hamper growth of the global market to a certain extent.

The Anti-CD20 Monoclonal Antibodies Market is segmented based on product type, end-user, and region

On the basis of product type, the Anti-CD20 Monoclonal Antibodies Market is segmented into First Generation Anti-CD20 Monoclonal Antibodies, Second Generation Anti-CD20 Monoclonal Antibodies, and Third Generation Anti-CD20 Monoclonal Antibodies. Based on end-user, the target market is segmented into hospitals, clinics, academic & research institutions and contract research organizations (CRO’s).

Regional Insights:

On region the Anti-CD20 Monoclonal Antibodies Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is dominates the global market with the largest market share due to the presence of sophisticated healthcare infrastructure, proper reimbursement of therapy procedure, and increasing awareness about personalized medicines among the population. Europe is the second dominating region after North America.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the Global Anti-CD20 Monoclonal Antibodies Market report based on product type, end-user, and region.

Anti-CD20 Monoclonal Antibodies Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the Anti-CD20 Monoclonal Antibodies Market include Biogen, Inc., Genentech, Inc. (F. Hoffmann-La Roche AG), Genmab A/S, Immunomedics, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Bio-Rad Laboratories, Inc., and LFB Biotechnologies S.A. Companies are continuously rising the production and improving supply of antibodies.

Recent Develpoments:

In December 2023, The Ministry of Health, Labour, and Welfare (MHLW) approved Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. to use of anti-CD20 monoclonal antibody Rituxan® intravenous injections of 100 mg and 500 mg to suppress and treat antibody-mediated rejection in organ transplantation. The anti-CD20 monoclonal antibody rituxan binds only to the CD20 protein, which is expressed on B cells only—hematopoietic stem cells and plasma cells are not included. It uses the immune system that the human body has developed to assault target B cells and causes cell damage. This mechanism of action inhibits B cells from differentiating into cells that produce antibodies, which is anticipated to inhibit the generation of antibodies for organ transplant recipients.

• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Biogen, Inc.
•  Genentech Inc. (F. Hoffmann-La Roche AG)
•  Genmab A/S
• Immunomedics, Inc.
•  Novartis AG
•  Spectrum Pharmaceuticals Inc.
• LFB Biotechnologies S.A.

 “*” marked represents similar segmentation in other categories in the respective section